KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Taxes (2009 - 2011)

Alnylam Pharmaceuticals posted quarterly Change in Taxes of -$10.7 million for Q1 2011, down 92.37% year-on-year from -$139.9 million in Q1 2010, and down 35663.33% on a QoQ basis from $30000.0 in Q4 2010.

Alnylam Pharmaceuticals (ALNY) has 3 years of Change in Taxes data on file, last reported at -$10.7 million in Q1 2011.

  • For the quarter ending Q1 2011, Change in Taxes fell 92.37% year-over-year to -$10.7 million; the trailing twelve-month figure through Dec 2011 stood at -$10.7 million (down 93.42% YoY), and the FY2011 full-year result was -$10.7 million, down 93.42% from the prior year.
  • Change in Taxes for Q1 2011 stood at -$10.7 million, down from $30000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $4.3 million in Q4 2009 and bottomed at -$10.7 million in Q1 2011.
  • The 3-year median for Change in Taxes is -$1000.0 (2010), against an average of -$1.8 million.
  • Peak annual rise in Change in Taxes reached 100.2% in 2010, while the deepest fall reached 99.31% in 2010.
  • A 3-year view of Change in Taxes shows it stood at $4.3 million in 2009, then slumped by 99.31% to $30000.0 in 2010, then sank by 35663.33% to -$10.7 million in 2011.
  • The last three Change in Taxes figures came in at -$10.7 million (Q1 2011), $30000.0 (Q4 2010), and $1000.0 (Q3 2010), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Taxes (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2011 -10.67 Mn
Mar 31, 2011 -10.67 Mn
Dec 31, 2010 30,000.00
Dec 31, 2010 30,000.00
Sep 30, 2010 1,000.00
Sep 30, 2010 1,000.00
Jun 30, 2010 -1,000.00
Jun 30, 2010 -1,000.00
Mar 31, 2010 -5.55 Mn
Mar 31, 2010 -5.55 Mn
Dec 31, 2009 4.33 Mn
Dec 31, 2009 4.33 Mn
Sep 30, 2009 -512,000.00
Sep 30, 2009 -512,000.00